3 Companies Team Up to Develop SF2523 for PF, Cancer, COVID-19

3 Companies Team Up to Develop SF2523 for PF, Cancer, COVID-19

305548

3 Companies Team Up to Develop SF2523 for PF, Cancer, COVID-19

A trio of global companies is teaming up to develop an inhaled dry powder formulation of SF2523, an investigational small molecule that blocks the activity of two fibrosis-driving proteins that may help block tumor growth and ease lung scarring and inflammation. SF2523 is being developed as a treatment for pulmonary fibrosis (PF) and other inflammatory conditions, as well as for lung cancer and COVID-19. The new collaboration is a three-way effort between SignalRx Pharmaceuticals, a…

You must be logged in to read/download the full post.